Lindbrook Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Lindbrook Capital, LLC

  • $1.18 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 28, 2023
SELL
$8.48 - $16.48 $16,960 - $32,960
-2,000 Reduced 95.33%
98 $1,000
Q1 2023

Apr 26, 2023
BUY
$6.41 - $9.95 $1,282 - $1,989
200 Added 10.54%
2,098 $19,000
Q4 2022

Jan 24, 2023
SELL
$5.02 - $10.0 $943 - $1,880
-188 Reduced 9.01%
1,898 $0
Q3 2022

Nov 10, 2022
BUY
$2.57 - $7.31 $735 - $2,090
286 Added 15.89%
2,086 $10,000
Q2 2022

Aug 01, 2022
BUY
$1.07 - $6.95 $1,926 - $12,510
1,800 New
1,800 $4,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email